Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Endo (ENDP) Q2 Earnings Beat Estimates, 2017 Guidance Cut
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.
What's in the Cards for Endo (ENDP) this Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) remains focused on providing updates on its restructuring efforts across the Generics product as well as its manufacturing facility network in Q2.
Options Traders Expect Huge Moves in Endo International (ENDP) Stock
by Zacks Equity Research
Options Traders Expect Huge Moves in Endo International (ENDP) Stock on the back of its huge implied volatility
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.
Mallinckrodt to Pay $35M for Controlled Substances Probe
by Zacks Equity Research
Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.
Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market
by Zacks Equity Research
Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.
Is Endo International (ENDP) a Great Stock for Value Investors?
by Zacks Equity Research
Is Endo International a great pick from the value investor's perspective right now? Read on to know more.
Why Is Endo (ENDP) Down 4.7% Since the Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for June 12, 2017
by Zacks Equity Research
Companies in the News are: DFT,DLR,ENDP,P,SIRI,LXRX
Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down
by Zacks Equity Research
Endo International plc (ENDP) received a huge setback when the FDA directed the company to voluntarily remove its opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market over abuse concerns.
Intellipharmaceutics Announces Launch of Generic Seroquel XR
by Zacks Equity Research
Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company
BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
by Zacks Equity Research
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Endo (ENDP) Q1 Earnings Beat Estimates, Revenues in Line
by Madhu Goel
Endo surpassed first-quarter 2017 earnings. The company reported EPS of $1.23 while our consensus called for EPS of $1.12.
4 Drug Stocks Poised to Beat this Earnings Season
by Zacks Equity Research
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
What's in Store for BioDelivery (BDSI) this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.
BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.
Is Endo (ENDP) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell.
Generic Drugmakers Tumble as Perrigo Discloses DoJ Search
by Arpita Dutt
With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected
by Zacks Equity Research
IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.
Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for Endo International (ENDP) shares as it has huge implied volatility.
Endo (ENDP) Reports Preliminary Results for First Quarter
by Zacks Equity Research
Endo International plc (ENDP) recently announced preliminary results for first-quarter 2017.